Tirzepatide vs Semaglutide — molecule comparison for India
Tirzepatide vs semaglutide — what's the same, what's different, and questions to ask your doctor before deciding.
Overview
Tirzepatide vs Semaglutide: a structural comparison
Tirzepatide and semaglutide are the two GLP-1-pathway active ingredients available in India through 2026. Both are weekly subcutaneous injections, both are CDSCO-approved, and both are sold under several Indian brand names — tirzepatide as Mounjaro and Yurpeak, and semaglutide as Semaglyn, Wegovy India, and Obeda.
This page summarises what is structurally the same and what is structurally different between the two molecules. It is not a recommendation — choosing between them is a clinical decision your prescriber makes based on your history, tolerance, glycaemic targets, and what's actually stocked at your pharmacist.
For current Indian pharmacy prices across both molecules, see /price. For the standard titration ladders the label describes for each, see /tools/titration. To verify a pen you've already purchased, see /check.
At a glance
| Tirzepatide | Semaglutide | |
|---|---|---|
| Mechanism (per label) | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Half-life | ~5 days | ~7 days |
| Available weekly dose range | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.25, 0.5, 1, 1.7, 2.4 mg |
| Indian brands | [Mounjaro](/brands/mounjaro), [Yurpeak](/brands/yurpeak) | [Semaglyn](/brands/semaglyn), [Wegovy India](/brands/wegovy-india), [Obeda](/brands/obeda) |
| Common starting dose (label) | 2.5 mg weekly × 4 weeks | 0.25 mg weekly × 4 weeks |
| Route & frequency | Subcutaneous, once weekly | Subcutaneous, once weekly |
| Storage | Refrigerated 2–8 °C | Refrigerated 2–8 °C |
What's the same
What's structurally the same
At a structural level, tirzepatide and semaglutide have more in common than the marketing suggests:
- Route and frequency. Both are once-weekly subcutaneous injections, typically into the abdomen, thigh, or upper arm. Both come as pre-filled pens in India.
- Pathway overlap. Both act on the GLP-1 receptor. Tirzepatide adds a GIP component on top — semaglutide does not.
- Titration philosophy. Both labels describe a stepwise ladder, generally 4 weeks per dose step before moving up. Standard ladders are summarised at /tools/titration.
- Storage. Both pens are stored refrigerated at 2–8 °C before first use, per the label.
- Regulatory status. Both are CDSCO-approved in India and dispensed by prescription.
- Side-effect family. The most commonly reported side effects for both — nausea, reduced appetite, mild reflux, occasional loose stools or constipation — sit in the same GI cluster, because both act through the GLP-1 pathway.
In other words: the category of medicine is the same. The differences are in the details.
What's different
What's structurally different
Mechanism. Tirzepatide is a dual agonist — it activates both the GIP and GLP-1 receptors. Semaglutide activates GLP-1 only. The clinical implication of the GIP component is still being characterised; trials describe somewhat different average weight and HbA1c responses, but individual response varies and your doctor is the right person to interpret those numbers for your situation.
Half-life. Semaglutide has a longer half-life (~7 days) than tirzepatide (~5 days). Both still support weekly dosing per the label.
Dose units don't translate. A "5 mg" dose of tirzepatide is not equivalent to "5 mg" of semaglutide — the ladders are entirely separate. Tirzepatide ladders go 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Semaglutide ladders go 0.25 → 0.5 → 1 → 1.7 → 2.4 mg. Never assume a number on one translates to the other.
Side-effect intensity patterns. Both share the GI side-effect family, but many patients commonly report that the intensity and timing feel different between the two. Some tolerate one molecule noticeably better than the other — this is individual.
Indian brand availability. Tirzepatide is currently available in India as Mounjaro (Eli Lilly) and Yurpeak (Cipla). Semaglutide has wider brand availability: Semaglyn (Zydus), Wegovy India (Novo Nordisk), and Obeda (Dr Reddy's). Stock at any given Apollo, Tata 1mg, Pharmeasy or Netmeds varies week to week.
Price. Pricing per month differs meaningfully and changes often — see /price for current ₹ figures.
Questions to ask your doctor
Questions worth asking your doctor
Before choosing between tirzepatide and semaglutide, these are conversation prompts — not conclusions:
- What's the primary goal you're treating — glycaemic control, weight, or both? The answer may shape molecule choice.
- Do I have any history (pancreatitis, thyroid, gallbladder, severe GI issues) that makes one molecule less appropriate for me?
- Which brand is reliably stocked at the pharmacist I actually use? Continuity matters more than the molecule on paper.
- What does the titration ladder look like for me, and what should I do if I don't tolerate a step?
- How will we measure whether this is working, and at what point would we reconsider?
If you've already started one molecule and are wondering about switching, that's specifically a clinical decision — please consult your doctor rather than self-adjusting. You can also verify any pen you've purchased at /check.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
Head-to-head trials describe larger average weight and HbA1c reductions with tirzepatide at higher doses, but "stronger" is a misleading word. Individual response varies widely, side-effect tolerance varies, and the dose you actually end up on matters more than the molecule label. Your doctor is the right person to interpret what the trial averages mean for your situation.
If I tolerate one well, is there a reason to switch?
Generally, no — tolerance and consistent supply are valuable. People sometimes discuss switching with their doctor for reasons like plateauing response, cost, or persistent side effects on the current molecule. This is a clinical decision and not something to do on your own. Consult your doctor before any switch.
Are the side effects the same?
They sit in the same family — nausea, reduced appetite, mild reflux, occasional loose stools or constipation — because both act on the GLP-1 pathway. Many patients commonly report that the *intensity* and *timing* feel different between the two molecules, and some tolerate one noticeably better than the other. There is no way to predict which will suit you without trying under medical supervision.
Which is cheaper in India?
Prices change frequently and depend on dose, brand, and pharmacist. As a general pattern through 2026, semaglutide brands like Semaglyn and Obeda often sit at a lower monthly ₹ figure than tirzepatide brands, but this is not universal across all doses. See [/price](/price) for current Indian pharmacy prices.
Can I use the same titration ladder for both?
No. The dose units are completely different — 5 mg of tirzepatide is not comparable to 5 mg of semaglutide. Each molecule has its own ladder described on its label. See [/tools/titration](/tools/titration) for the standard ladders, and consult your doctor for the one that applies to you.
Are both available in India in 2026?
Yes. Tirzepatide is available as Mounjaro (Eli Lilly) and Yurpeak (Cipla). Semaglutide is available as Semaglyn (Zydus), Wegovy India (Novo Nordisk), and Obeda (Dr Reddy's). All are CDSCO-approved and dispensed by prescription. Stock at Apollo, Tata 1mg, Pharmeasy, and Netmeds varies week to week.
Glipin is a tracking and educational tool. We are not your doctor and we do not give medical advice. We do not guarantee any pen is authentic. Always consult a licensed healthcare professional about your treatment.